Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?

Denali Therapeutics has delivered a mixed share price journey, with sharp gains over the past year sitting against a much weaker longer track record. That kind of profile puts the spotlight firmly on whether the current stock price is aligned with the cash flows that the business can realistically produce. Over 5 years, Denali Therapeutics shares have fallen 57.3%, which makes the current valuation question largely about whether the market is now paying the right price for a business that...